Vol. 4 No. 12 (2024)
Reimbursement Reviews

Brentuximab Vedotin (Adcetris)

decorative image of the issue cover

Published December 16, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses brentuximab vedotin for injection (Adcetris), 50 mg per vial, lyophilized powder for reconstitution, IV infusion.
  • Indication: For the treatment of previously untreated patients with stage IV Hodgkin lymphoma, in combination with doxorubicin, vinblastine, and dacarbazine.